CD86: the context-setting signal for T-cell activation
Function
CD86 is displayed by antigen-presenting cells and binds CD28 to support T-cell co-stimulation and CTLA-4 to help restrain responses. Its meaning depends on timing, receptor availability, and the activation state of both cells.
CD86 available
Antigen recognition receives a context signal that can support or regulate T-cell activation.
→
CD86 reduced
T-cell priming may weaken, but inflammatory output can also change because CTLA-4 engagement is lost.
The UC hypomethylation signal is biologically compatible with abundant/activated antigen-presenting cells, but does not prove CD86 overexpression. Bulk biopsy composition is a major competing explanation.
What the evidence adds
CD86 is not simply an “on” switch. CD28 and CTLA-4 share CD80/CD86 ligands but drive different outcomes, and B7-2/CD86 tends to appear early during antigen-presenting-cell activation (Sharpe and Freeman, 2002). More recent cell-biological work shows that CTLA-4 can physically remove CD86 from neighboring cells by transendocytosis; defects in that process can contribute to autoimmunity (Kennedy, Waters, Rowshanravan, and others, 2022). A biopsy methylation value therefore sits several regulatory steps upstream of the biologically relevant quantity: receptor engagement at an APC–T-cell contact.
Biomarker interpretation
A useful CD86 result would distinguish within-cell epigenetic change from recruitment of CD86-positive dendritic cells, monocytes, or B cells. Paired single-cell or spatial expression, immune-cell proportions, and protein localization would make a bulk DMR interpretable. Until then, CD86 hypomethylation is best described as an immune-state candidate marker, not evidence of net CD28 or CTLA-4 signaling.